What is Zacks Research's Forecast for Alkermes Q2 Earnings?

Alkermes plc (NASDAQ:ALKS - Free Report) - Investment analysts at Zacks Research reduced their Q2 2025 earnings per share estimates for Alkermes in a report released on Monday, January 6th. Zacks Research analyst R. Department now anticipates that the company will earn $0.31 per share for the quarter, down from their prior estimate of $0.33. The consensus estimate for Alkermes' current full-year earnings is $2.25 per share. Zacks Research also issued estimates for Alkermes' Q3 2025 earnings at $0.33 EPS, Q4 2025 earnings at $0.36 EPS, Q1 2026 earnings at $0.35 EPS and FY2026 earnings at $1.56 EPS.

A number of other equities research analysts have also issued reports on the stock. Cantor Fitzgerald cut their target price on shares of Alkermes from $48.00 to $43.00 and set an "overweight" rating on the stock in a research note on Friday, October 25th. HC Wainwright reaffirmed a "neutral" rating and set a $37.00 target price on shares of Alkermes in a report on Friday, October 25th. Stifel Nicolaus upgraded Alkermes from a "hold" rating to a "buy" rating and boosted their price target for the company from $25.00 to $36.00 in a report on Tuesday, November 5th. JPMorgan Chase & Co. reduced their price objective on Alkermes from $32.00 to $26.00 and set a "neutral" rating on the stock in a research note on Friday, October 25th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $37.00 price objective (down previously from $38.00) on shares of Alkermes in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $36.00.

Alkermes Stock Down 0.4 %

Shares of ALKS traded down $0.12 during trading on Wednesday, reaching $28.42. The company's stock had a trading volume of 1,613,974 shares, compared to its average volume of 1,348,575. Alkermes has a twelve month low of $22.90 and a twelve month high of $32.88. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The company has a market cap of $4.60 billion, a price-to-earnings ratio of 14.57, a P/E/G ratio of 1.03 and a beta of 0.49. The company has a fifty day moving average of $29.17 and a two-hundred day moving average of $27.63.

Insider Transactions at Alkermes

In other news, SVP Christian Todd Nichols sold 5,208 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $29.15, for a total value of $151,813.20. Following the completion of the sale, the senior vice president now directly owns 60,703 shares of the company's stock, valued at approximately $1,769,492.45. This represents a 7.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Cato T. Laurencin sold 2,691 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $31.85, for a total transaction of $85,708.35. Following the completion of the transaction, the director now owns 23,013 shares of the company's stock, valued at $732,964.05. This trade represents a 10.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 147,738 shares of company stock worth $4,572,904. Company insiders own 4.89% of the company's stock.

Institutional Investors Weigh In On Alkermes

Institutional investors have recently added to or reduced their stakes in the company. V Square Quantitative Management LLC bought a new position in shares of Alkermes during the 3rd quarter valued at about $29,000. GAMMA Investing LLC boosted its holdings in Alkermes by 83.8% during the third quarter. GAMMA Investing LLC now owns 4,204 shares of the company's stock worth $118,000 after buying an additional 1,917 shares in the last quarter. Archer Investment Corp grew its position in Alkermes by 28.6% in the third quarter. Archer Investment Corp now owns 4,500 shares of the company's stock worth $126,000 after buying an additional 1,000 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new position in shares of Alkermes in the second quarter valued at $116,000. Finally, KBC Group NV lifted its position in shares of Alkermes by 18.8% during the 3rd quarter. KBC Group NV now owns 4,890 shares of the company's stock valued at $137,000 after acquiring an additional 774 shares during the last quarter. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.